Successful Amendment of an Existing Hepatitis B Screening Programme by a Guideline Recommended Hepatitis D Screening in the Primary Care Setting

Overview

Journal Aliment Pharmacol Ther

Specialties Gastroenterology
Pharmacology

Date 2024 Dec 4

PMID 39628411

Authors

Toni Herta

Anna Joachim-Richter

David Petroff

Benno Wolk

Ingmar Wolffram

Thomas Berg

Jan Kramer

Olaf Batz

Johannes Wiegand

Affiliations

Soon will be listed here.

Abstract

Background: Despite European guidelines recommending anti-hepatitis D virus (HDV) screening for all hepatitis B surface antigen (HBsAg)-positive cases, screening rates remain insufficient.

Aims: We analysed anti-HDV screening rates in primary care and implemented prospective HDV screening in HBsAg-positive cases identified in the preventive medical examination from the age of 35 ("Check-Up 35+").

Methods: From 2012 to 2021, we reviewed anti-HDV and HDV RNA test rates in HBsAg-positive patients at 11 sites of a large German laboratory group. From 2022 to 2023, we prospectively screened HBsAg-positive samples from the "Check-Up 35+" for anti-HDV. Anti-HDV positive patients were then contacted again for HDV RNA testing.

Results: Retrospectively, 2792/13,905 (20%) HBsAg-positive cases were tested for anti-HDV, with 142/2792 (5.1%) being positive. HDV RNA was tested in 57/142 (40%) anti-HDV-positive cases, with 26/57 (46%) being positive. In the prospective screening, 1159/225,901 (0.51%) individuals were HBsAg-positive. Of these, 700 (60%) were tested for anti-HDV, with 18/700 (2.6%) positive test results. 4/18 (22%) were successfully contacted again for HDV RNA analysis, with one case testing positive. Neither the HBsAg nor the anti-HDV positive result was known prior to screening in these cases. Anti-HDV testing could not be performed in 459/1159 (40%) HBsAg-positive cases, primarily due to insufficient blood sample volume (310/459 cases, 68%), with others missed due to logistical errors.

Conclusions: Retrospective data show insufficient anti-HDV screening in clinical routine. The prospective anti-HDV screening provides a blueprint for using existing hepatitis B virus screening programms for population-based HDV double reflex testing, provided that adequate logistical prerequisites are established.

Trial Registration: German Clinical Trial Register: DRKS00029180.

References

Dietz-Fricke C, Tacke F, Zollner C, Demir M, Schmidt H, Schramm C . Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. JHEP Rep. 2023; 5(4):100686. PMC: 10071092. DOI: 10.1016/j.jhepr.2023.100686. View

Lazarus J, Al-Rifai A, Sanai F, Alghamdi A, Sharara A, Saad M . Hepatitis delta virus infection prevalence, diagnosis and treatment in the Middle East: A scoping review. Liver Int. 2022; 43 Suppl 1:116-123. DOI: 10.1111/liv.15338. View

Parfut A, Tripon S, Gantner P, Chaffraix F, Laugel E, Wendling M . Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France: Support for primary HDV screening in France. J Clin Virol. 2024; 171:105650. DOI: 10.1016/j.jcv.2024.105650. View

Huppe D, Wedemeyer H, Cornberg M . Population-based screening works: Effect of integrating screening for hepatitis B and C into the general health check-up in Germany. J Hepatol. 2023; 80(4):e174-e176. DOI: 10.1016/j.jhep.2023.10.034. View

Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M . Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016; 65(3):490-8. DOI: 10.1016/j.jhep.2016.04.016. View

. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023; 79(2):433-460. DOI: 10.1016/j.jhep.2023.05.001. View

Cooke G, Flower B, Cunningham E, Marshall A, Lazarus J, Palayew A . Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update. Lancet Gastroenterol Hepatol. 2024; 9(4):346-365. DOI: 10.1016/S2468-1253(23)00321-7. View

Canbay A, Kachru N, Haas J, Meise D, Ozbay A, Sowa J . Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann Transl Med. 2021; 9(8):615. PMC: 8106103. DOI: 10.21037/atm-20-7179. View

Wedemeyer H, Schoneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T . Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2022; 23(1):117-129. DOI: 10.1016/S1473-3099(22)00318-8. View

10.

Terrault N, Lok A, McMahon B, Chang K, Hwang J, Jonas M . Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67(4):1560-1599. PMC: 5975958. DOI: 10.1002/hep.29800. View

11.

Hoebel J, Richter M, Lampert T . Social status and participation in health checks in men and women in Germany: results from the German Health Update (GEDA), 2009 and 2010. Dtsch Arztebl Int. 2013; 110(41):679-85. PMC: 3813884. DOI: 10.3238/arztebl.2013.0679. View

12.

Erhardt A, Hoernke M, Heinzel-Pleines U, Sagir A, Gobel T, Haussinger D . Retrospective analysis of chronic hepatitis D in a West German University Clinic over two decades: migratory pattern, prevalence and clinical outcome. Z Gastroenterol. 2010; 48(8):813-7. DOI: 10.1055/s-0028-1109984. View

13.

Razavi H, Buti M, Terrault N, Zeuzem S, Yurdaydin C, Tanaka J . Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries. J Hepatol. 2023; 79(2):576-580. DOI: 10.1016/j.jhep.2023.02.041. View

14.

Sarin S, Kumar M, Lau G, Abbas Z, Chan H, Chen C . Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2015; 10(1):1-98. PMC: 4722087. DOI: 10.1007/s12072-015-9675-4. View

15.

Wedemeyer H, Leus M, Battersby T, Glenn J, Gordien E, Kamili S . HDV RNA assays: Performance characteristics, clinical utility, and challenges. Hepatology. 2023; 81(2):637-650. PMC: 11289715. DOI: 10.1097/HEP.0000000000000584. View

16.

Dietz-Fricke C, Degasperi E, Jachs M, Maasoumy B, Reiter F, Geier A . Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series. Hepatology. 2024; 80(3):664-673. PMC: 11332372. DOI: 10.1097/HEP.0000000000000847. View

17.

Gish R, Wong R, Di Tanna G, Kaushik A, Kim C, Smith N . Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis. Hepatology. 2023; 79(5):1129-1140. PMC: 11019996. DOI: 10.1097/HEP.0000000000000642. View

18.

Zollner C, Hofmann J, Lutz K, Tacke F, Demir M . Real-life experiences with bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre. Liver Int. 2022; 42(11):2403-2407. DOI: 10.1111/liv.15408. View

19.

Jachs M, Schwarz C, Panzer M, Binter T, Aberle S, Hartl L . Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a "real world" study. Aliment Pharmacol Ther. 2022; 56(1):144-154. PMC: 9321570. DOI: 10.1111/apt.16945. View

20.

C Reinheimer , Doerr H, Berger A . Hepatitis delta: on soft paws across Germany. Infection. 2012; 40(6):621-5. DOI: 10.1007/s15010-012-0287-9. View